Last reviewed · How we verify
Receipt of enoxaparin
Enoxaparin is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa.
Enoxaparin is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Prophylaxis of deep vein thrombosis (DVT) in patients undergoing abdominal surgery or hip/knee replacement, Treatment of acute DVT and pulmonary embolism, Acute coronary syndrome (unstable angina and non-ST-segment elevation myocardial infarction).
At a glance
| Generic name | Receipt of enoxaparin |
|---|---|
| Sponsor | University of Utah |
| Drug class | Low-molecular-weight heparin (LMWH) |
| Target | Factor Xa and Factor IIa (via antithrombin III) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Enoxaparin binds to and potentiates antithrombin III, a natural anticoagulant, leading to inactivation of coagulation factors Xa and IIa. This prevents thrombin generation and fibrin clot formation. It is administered subcutaneously and has more predictable pharmacokinetics than unfractionated heparin.
Approved indications
- Prophylaxis of deep vein thrombosis (DVT) in patients undergoing abdominal surgery or hip/knee replacement
- Treatment of acute DVT and pulmonary embolism
- Acute coronary syndrome (unstable angina and non-ST-segment elevation myocardial infarction)
- Prevention of ischemic complications in patients with acute ST-segment elevation myocardial infarction
Common side effects
- Bleeding
- Thrombocytopenia
- Injection site hematoma
- Elevated liver enzymes
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Receipt of enoxaparin CI brief — competitive landscape report
- Receipt of enoxaparin updates RSS · CI watch RSS
- University of Utah portfolio CI